Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trialMasaaki Kondo, Katsuaki Tanaka, Satoshi Kobayashi et al.|BMC Cancer|2019Cited by 77
Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenibManabu Morimoto, Katsuaki Tanaka, Satoshi Kobayashi et al.|Hepatology Research|2011Cited by 77
Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinomaJuichi Takada, Wasaburo Koizumi, Hisashi Hidaka et al.|BMC Research Notes|2015Cited by 43
Field practice study of half‐dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: A propensity score analysisManabu Morimoto, Katsuaki Tanaka, Kazushi Numata et al.|Hepatology Research|2014Cited by 30
Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: A propensity score‐based weightingMasaaki Kondo, Katsuaki Tanaka, Manabu Morimoto et al.|Journal of Digestive Diseases|2014Cited by 20